Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
about
Importance of circulating antibodies in protection against meningococcal diseaseImmune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.The role of apolipoprotein N-acyl transferase, Lnt, in the lipidation of factor H binding protein of Neisseria meningitidis strain MC58 and its potential as a drug target.Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal VaccinationAntibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.Mechanisms of microbial traversal of the blood-brain barrier.Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.Vaccine development against Neisseria meningitidis.Herd immunity: recent uses in vaccine assessment.Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.Prevention of meningococcal serogroup C disease by NeisVac-C.Treatment strategies for central nervous system infections.Expanding prevention of invasive meningococcal disease.Optimizing protection against meningococcal disease.Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and WalesUsing the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease.Specialty Grand Challenge In Pediatric Infectious Diseases.
P2860
Q27023516-230C6561-3223-4A87-97FF-764819B936BDQ34627685-0DDA522B-79E1-42CE-AECA-4CF2C31FD436Q34955474-34AFA841-36E7-4E1C-AAF5-456F87E9223AQ35191903-D88A7AE1-3897-49EA-AEC1-3C0234B7505EQ35799561-57AC0F75-5124-45DF-847D-468CF8C64FFAQ36175206-F14A3CAC-A09A-4EC4-83B3-A724402E418BQ36265012-9D7BC636-0EA2-470E-9DA8-A04EE0D0F3ABQ36265103-7FE1F492-8C3B-4F54-803D-3362FEDF042FQ36391874-3E040DD7-886C-4C32-98A6-3F2449F11645Q36781534-1929DB98-95D2-47E4-A6B5-196DF925E27DQ36849830-B943D8FA-C8B0-4E2E-A22F-E485E5E0EF82Q36974336-B8022BA5-0E64-4920-8476-864F9266A6EFQ37208293-20624953-F896-4B81-93B3-89A14ECCA378Q37252405-325B9DD9-2DAF-4FF5-89E9-A2218170D4C5Q37274707-149D177F-0472-4AB8-9473-2AE4BAC1ECE5Q37340454-30C9BA53-17CF-4CDC-BBEC-E823D1053CC8Q37353525-BA416E24-393D-41D4-B1A0-C3764F602FA4Q37403478-06E7D07B-440D-42AE-937C-E8525E89DF0FQ37483938-8E2FF96B-6F8C-45DE-9F80-A9C01029E813Q37503239-A5063CAD-5EBA-4C9C-881D-151E332D896DQ37678717-E01C5EAA-2877-4AF9-AFD8-38537278D19EQ41812746-2D68C3D6-024A-4098-8ADE-90BDB9FDD66CQ41845489-B32E58CF-2860-447D-813D-464DF96D8B59Q41932534-031BBDB6-27C9-4C7A-A856-A5C030A74FEFQ50143779-08542C19-69DC-40C9-81AF-131B1952C872
P2860
Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Long-term protection in childr ...... vaccination: lessons learned.
@ast
Long-term protection in childr ...... vaccination: lessons learned.
@en
type
label
Long-term protection in childr ...... vaccination: lessons learned.
@ast
Long-term protection in childr ...... vaccination: lessons learned.
@en
prefLabel
Long-term protection in childr ...... vaccination: lessons learned.
@ast
Long-term protection in childr ...... vaccination: lessons learned.
@en
P2860
P356
P1476
Long-term protection in childr ...... vaccination: lessons learned.
@en
P2093
Elizabeth Miller
P2860
P304
P356
10.1586/14760584.5.6.851
P50
P577
2006-12-01T00:00:00Z